1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48 (1 Suppl 1):S27-S49. doi:10.2337/dc25-S002.
2. Дедов И. И., Шестакова М. В., Галстян Г. Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12. doi:10.14341/DM2004116-17.
3. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. doi:10.1007/s11906-018-0812-z.
4. Højlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. Dan Med J. 2014;61(7):B4890.
5. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-36. doi:10.1161/ATVBAHA.107.151092.
6. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278-316. doi:10.1210/er.2015-1137.
7. Thaler JP, Yi CX, Schur EA, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012;122(1):153-62. doi:10.1172/JCI59660.
8. Gou Y, Glat M, Damian V, et al. AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes. J Clin Invest. 2025;135(10):e189842. doi:10.1172/JCI189842.
9. Cercato C, Fonseca FA. Cardiovascular risk and obesity. Diabetol Metab Syndr. 2019;11:74. doi:10.1186/s13098-019-0468-0.
10. Møller CL, Vistisen D, Færch K, et al. Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study. J Clin Endocrinol Metab. 2016;101(2):485-93. doi:10.1210/jc.2015-3133.
11. Hartstra AV, Bouter KE, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015;38(1):159-65. doi:10.2337/dc14-0769.
12. Драпкина О. М., Корнеева О. Н. Кишечная микробиота и ожирение. Патогенетические взаимосвязи и пути нормализации кишечной микрофлоры. Терапевтический архив. 2016;88(9):135-42. doi:10.17116/terarkh2016889135-142.
13. Kononova YA, Likhonosov NP, Babenko AY. Metformin: Expanding the Scope of Application — Starting Earlier Than Yesterday, Canceling Later. Int. J. Mol.Sci. 2022;23:2363. doi:10.3390/ijms23042363.
14. Бабенко А. Ю. Метформин при предиабете: ключевые механизмы профилактики диабета и кардиометаболических рисков. Медицинский Совет. 2022;(10):96-103. doi:10.21518/2079-701X-2022-16-10-96-103.
15. Holm JC, Gamborg M, Ward LC, et al. Tracking of leptin, soluble leptin receptor, and the free leptin index during weight loss and regain in children. Obes Facts. 2011;4(6): 461-8. doi:10.1159/000335121.
16. Bourebaba L, Marycz K. Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review. J Clin Med. 2019;8(12):2033. doi:10.3390/jcm8122033.
17. Jayakrishnan B. Hepato-pancreatic fat-fetuin A based axis in context of diabetes and its reversal. Int J Adv Med. 2023;10:117-9. doi:10.18203/2349-3933.ijam20223413.
18. Lee CH, Lui DTW, Lam KSL. Adipocyte Fatty Acid-Binding Protein, Cardiovascular Diseases and Mortality. Front Immunol. 2021;12:589206. doi:10.3389/fimmu.2021.589206.
19. Heiker JT. Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. J Pept Sci. 2014;20(5):299-306. doi:10.1002/psc.2621.
20. Aibara D, Matsuo K, Yamano S, Matsusue K. Insulin induces expression of the hepatic vaspin gene. Endocr J. 2020;67(1):9-14. doi:10.1507/endocrj.EJ19-0276.
21. Stefan N, Fritsche A, Schick F, Häring HU. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol. 2016;4(9):789-98. doi:10.1016/S2213-8587(16)00082-6.
22. Wagner R, Heni M, Tabák AG, et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021;27(1):49-57. doi:10.1038/s41591-020-1116-9.
23. Zhang X, Gregg EW, Williamson DF, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010;33(7):1665-73. doi:10.2337/dc09-1939.
24. Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. doi:10.1136/bmj.m2297.
25. Hsu JC, Yang YY, Chuang SL, et al. Prediabetes increases the risk of major limb and cardiovascular events. Cardiovasc Diabetol. 2023;22(1):348. doi:10.1186/s12933-023-02085-y.
26. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-62. doi:10.1016/S2213-8587(24)00316-4.
27. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines, on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031.
28. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-16. doi:10.1056/NEJMoa2206038.
29. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008;102(12A):5L-9L. doi:10.1016/j.amjcard.2008.09.067.
30. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156(1):112-9. doi:10.1016/j.ahj.2008.03.005.
31. Hoogwerf BJ. Statins may increase diabetes, but benefit still outweighs risk. Cleve Clin J Med. 2023;90(1):53-62. doi:10.3949/ccjm.90a.22069.
32. Banach M, Surma S, Reiner Z, et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol. 2022;21(1):263. doi:10.1186/s12933-022-01684-5.
33. Maki KC, Ridker PM, Brown WV, et al. The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S17-29. doi:10.1016/j.jacl.2014.02.012.
